NovartisㆍAZㆍSanofiㆍRoche achieved 400 billion won mark
BayerㆍGSKㆍJanssen passed 300 billion won mark
Last year, domestic pharmaceutical companies remained at a low growth rate of early 5%, while foreign pharmaceutical companies gained ground, posting an average growth rate of over 15%.
According to the tally of the performances of 25 foreign pharmaceutical companies which submitted an audit report by the 9th, the average sales growth rate of 23 companies, which can be compared to 2018, reached 15.2%.
Compared with the average sales growth rate of domestic pharmaceutical companies during the same period, it was nearly three times higher, and 13 companies, more than half of the 23 companies, enjoyed a boom with double-digit growth.
However, operating profit and net profit increased by 4.5% and 5.5% respectively, which was only one-third of sales growth, therefore showed a drop in operating profit rate and net profit rate.
By company, Alcon’s growth was most noticeable. Alcon sales, which had just surpassed 100 billion won in 2018, surged 63.5% to 165 billion won last year.
AbbVie also achieved 42.6% growth with Mavyret, which posted annual sales of nearly 60 bilion won(based on IQVIA) last year, the following year of launch in late 2018. AbbVie sales increased sharply from 110.3 billion won in 2018 to 157.3 billion won last year.
Novo Nordisk, which is making a splash with the obesity treatment drug Saxenda, also increased its sales to 165.2 billion won with a growth rate of 24.5%.
Sanofi-Aventis saw its sales surge 17.7% to 438.3 billion won from 370 billion won mark in 2018, with a merger with Genzyme last year, going straight to 400 billion won mark.
Janssen also reached 300 billion won mark with a growth rate of 17.5% in the same period, while Lundbeck and Roche achieved a 15% growth rate which exceeded the average.
In addition, AstraZeneca, Guerbet, Boehringer Ingelheim, Servier, Otsuka, Fresenius Kabi recorded double-digit growth rates.
On the other hand, Janssen Vaccines sales were not counted last year, while sales of GSK Consumer Healthcare, Sandoz, UCB, Allergan, and Bayer fell from 2018.
Last year, Novartis Korea posted the highest sales of 493.4 billion won. Although it had been suffered from reverse growth and sluggish since exceeding 450 billion won in 2015, it has recovered its growth trend since 2018, and is expected to reach 500 billion won mark.
In particular, as Pfizer, which exceeded 700 billion won, was divided into Pfizer Pharmaceuticals, Pfizer Upjohn, and Pfizer Consumer Healthcare, Novartis became the top foreign pharmaceutical company in sales.
Following Novartis, the three companies including AstraZeneca, Sanofi-Aventis, and Roche, which recorded sales of 370~380 billion won in 2018, joined the companies with 400 billion won mark last year with a growth rate of 14~18%.
The three companies’s annual sales stood at 430 billion won mark last year, with AstraZenca at 438.9 billion won, Sanofi-Aventis at 438.3 billion won and Roche at 433.7 billion won.
Along with them, Bayer had posted sales of 370 billion won mark in 2018, but last year, sales growth went into reverse, topped out at 370 billion won mark.
Pfizer, which was the top foreign pharmaceutical company in 2018, reported sales of 374.1 billion won for Pfizer Pharmaceuticals and 179.9 billion won for Pfizer Upjohn after the division.
Following Pfizer Pharmaceuticals, GSK and Janssen entered 300 billion won mark with 316.5 billion won and 310 billion won in sales, respectively. Boehringer Ingelheim increased its sales to 295.3 billion won, nearing 300 billion mark.
Otsuka Pharmaceutical sales increased from 160 billion won mark to 180.2 billion won, reached close to 200 billion won mark. Novo Nordisk and Alcon reported sales of 165 billion won mark side by side, and AbbVie sales exceeded 150 billion won mark with 157.3 billion won.
On the contrary, GSK Consumer Healthcare retreated from 100 billion won mark with sales of 97.2 billion won, down from 110 billion won. It was followed by Sanofi Pasteur, Kyowa Kirin, Allergan, and Fresenius Kabi with 70 billion mark, Lundbeck with 60 billion mark and UCB with 50 billion mark.
Servier and Guerbet sales climbed from 30 billion won mark to 40 billion won mark, and Sandoz sales stayed at 20 billion won mark.
However, in the meantime, Novartis’s operating profit plunged to 6.1 billion won, despite of its sales growth, compared to 40 billion won mark in 2018.
Roche also is in the red, despite its sales increased significantly, reaching 400 billion won mark. Pfizer reported that the deficit continued.
On the other hand, GSK and Alcon came out of the red. Sanofi-Aventis’s operating profit increased significantly from 20.7 billion won to 34.8 billion won.
Furthermore, Otsuka Pharmaceutical’s operating profit rose sharply from 31.3 billion won in 2018 to 38.5 billion won last year, became the leader among foreign pharmaceutical companies.
In terms of net profit, all 25 companies are now in surplus as GSK Consumer Health and Guerbet turned into surplus.
But, Novartis’s net profit plunged by more than 70% to 6.7 billion won from 26.5 billion won, and Sandoz, an affiliate of Novartis, also saw its net profit slumped by more than 70% to 1 billion won from 4.4 billion won. Net profit of Bayer, Novo Nordisk and Kyowa Kirin fell by more than 40%.
Meanwhile, Janssen’s net profit surged nearly threefold, from 7.7 billion won to 21.2 billion won. Sanofi-Aventis’s net profit also nearly doubled to 20.8 billion won from 13.3 billion won and GSK‘s net profit doubled to 15.5 billion won from 8.1 billion won.